The therapeutic effect of a nutritional supplement consisting of a combination of glucosamine hydrochloride (FCHG49), purified sodium chondroitin sulfate (TRH122), and manganese ascorbate (GCM)3 was investigated in the rat model of collagen-induced autoimmune arthritis (CIA). The GCM compound was mixed with a palatable nutritional paste (Nutri-cal® [NC]). Oral administration of the NC/GCM compound was initiated in 26 rats 10 days before immunization and continued until the day of sacrifice. One group of 12 control rats was given no oral agents; a second group of 12 control rats received NC only. Evaluations included arthritis index (AI) scoring by three independent evaluators, histologic index (HI) scoring of lesions, T-cell proliferation, and serological studies for antibody classes and subclasses. Both the AI and HI criteria showed a statistically significant reduction in the prevalence of CIA in rats pretreated with the NC/GCM (54%) compared to the combined control groups (96%, χ2 analysis P < 0.001). Rats fed the NC/GCM also exhibited a significant decrease in the severity of autoimmune arthritis in both the AI and HI compared to control Group 2 (immunized-NC) (χ2 analysis P < 0.05). Histological studies verified the decreased incidence of arthritis in the NC/GCM group compared to control Group 2.
GCM treatment failed to alter T-cell proliferation and antibody production to bovine type-II collagen, indicating that its effects are not due to alteration of the antigen-specific immune response.
JacobsonDL, GangeJJ, RoseNR, GrahamNMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol84: 223–243, 1997.
2.
RosenbergA.Skeletal system and soft tissue tumors. In: CotranR, KumarV, RobbinsFL, Eds. Pathologic Basis of Disease (5th ed.). Philadelphia: W.B. Saunders. pp 1213–1271, 1994.
DavisWM. The role of glucosamine and chondroitin sulfate in the management of arthritis. Drug Topics142: 3S–13S, 1998.
9.
McNamaraPS, JohnstonSA, TodhunterRJ. Slow-acting, disease-modifying osteoarthritis agents. Vet Clin North Am: Small An Pract27: 863–891, 1997.
10.
JimenezSA, DodgeGR. The effects of glucosamine sulfate (GS04) on human chondrocyte gene expression. Osteoarthr Cartil5: 72, 1997.
11.
PipernoM, ReboulP, Hellio le GraverandMP, PeschardMJ, AnnefeldM, RichardM, VignonB.Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthr Cartil8: 207–212, 2000.
12.
UebelhartD, ThonarE, ZhangJ, WilliamsJ.Protective effect of exogenous chondroitin sulfate 4,6-sulfate in the acute degradation of articular cartilage in the rabbit. Osteoarthr Cartil6:(Suppl A):6–13, 1998.
GarrisonRH, SomerE Ed. NDR (The Nutrition Desk Reference). Minerals. New Canaan, CT: Keates Publishing Inc., p 70, 1985.
15.
SinghRK, KooremanKM, BabbsCF, FessierJF, SalarisSC. Potential use of simple manganese salts as antioxidant drugs in horses. Am J Vet Res53:(10): 1822–1829, 1992
16.
LeachRM. Role of manganese in mucopolysaccharide metabolism. Fed Proc30:(3):991, 1969.
17.
LippielloL, IdouraineA, McNamaraPS, BarrSC, McLaughlinRM. Cartilage stimulatory and antiproteolytic activity is present in sera of dogs treated with a chondroprotective agent. Canine Pract24: 1, 1999.
18.
HansonRR, SmalleyLR, HuffGK, WhiteS, HammadTA. Oral treatment with a glucosamine-chondroitin sulfate compound for degenerative joint disease in horses: 25 Cases. Equine Pract19: 16–22, 1997.
19.
HansonRR, HammadTA, BrawnerWR. Evaluation of the clinical efficacy of Cosequin® in the treatment of navicular syndrome—A double-blinded placebo controlled randomized clinical trial. Vet Orthop Soc, 25th Annual Conference. Madison, WI: Omni Press, p 63, February1998.
20.
AndersonMA, SlaterMR, HammadTA. Results of a survey of small-animal practitioners on the perceived clinical efficacy and safety of an oral nutraceutical. Prev Vet Med38: 65–73, 1999.
21.
WoodwardJR, LippielloL, KarpmanR.Beneficial effects of a dietary chondroprotective agent in a rabbit instability model of osteoarthritis. Anaheim, CA: Paper #48, 66th Annu Mtg Am Acad Orthop Surgeons, February 5, 1999.
22.
CanappSO, McLaughlinRM, HoskinsonJJ, RoushJK, ButineMD. Scintigraphic evaluation of glucosamine HCl and chondroitin sulfate as treatment for acute synovitis in dogs. Am J Vet Res60: 1550–1556, 1999.
23.
McNamaraPS, BarrSC, ErbHN. Hematologic, hemostatic, and biochemical effects in dogs receiving an oral chondroprotective agent for thirty days. Am J Vet Res57: 1390–1394, 1996.
24.
DasA, HammadTA. Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthr Cartil8: 343–350, 2000.
25.
LefflerCT, PhilippiAF, LefflerSG, MosureJC, KimPD. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind, placebo-controlled pilot study. Mil Med164:(2):85–91, 1999.
26.
NiebauerGW, WolfB, BasheyRI, NewtonCD. Antibodies to canine collagen types I and II in dogs with spontaneous cruciate ligament rupture and osteoarthritis. Arthr Rheum30: 319–327, 1987.
27.
CookeTD. Significance of immune complex deposits in osteoarthritic cartilage. J Rheumatol14:(Spec No):77–79, 1987.
28.
BariAS, CarterSD, BellSC, MorganK, BennettD.Anti-type II collagen antibody in naturally occurring canine joint diseases. Br J Rheumatol28: 480–486, 1989.
29.
GyntherGW, HolmlundAB, ReinholtFP, LindbladS.Temporomandibular joint involvement in generalized osteoarthritis and rheumatoid arthritis: A clinical, arthroscopic, histologic and immunohistochemical study. Int J Oral Maxillofac Surg26: 10–16, 1998.
30.
TrenthamDE, TownesAS, KangAH. Autoimmunity to type II collagen: An experimental model of arthritis. J Exp Med146: 857–868, 1977.
MagilavyDB. Animal models of chronic inflammatory arthritis. Clin Orthoped Related Res259: 38–45, 1990.
33.
GreenwaldRA, DiamondHS. The Handbook of Animal Models for the Rheumatic Diseases. Boca Raton, FL: CRC Press, Vol 1, p 23, 1988.
34.
SiegalS, CastellanNJ. Nonparametric statistics for the behavioral sciences. New York: McGraw-Hill, Inc., 1988.
35.
ConteA, VolpiN, PalmieriL, BahousI, RoncaG.Biochemical and Pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimittel Forschg45: 918–925, 1995.
36.
Muller-FaßbenderH.Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis. Am J Med83:(5A):81–83, 1987.
37.
SetnikarI, PacinicMA, RevelL.Antiarthritic effects of glucosamine sulfate studied on animal models. Arzneimittel-Forschg41: 542–545, 1991.
38.
UebelhardtD, ThonarEJMA, DelmasPD, ChantraineA, VignonE.Effects of oral chondroitin sulfate on the progression of knee osteoarthritis. Osteoarthr Cartil6:(Suppl):39–46, 1998.
39.
VerbruggenG, GoemaereS, VeysEM. Chondroitin sulfate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint osteoarthritis. Osteoarthr Cartil6:(Suppl A):37–38, 1998.
40.
LippielloL, WoodwardJ, KarpmanR, HammadTA. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate. Clin Orthop Relat Res381: 229–230, 2000.
